Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion

被引:69
作者
Nithipatikom, K
Isbell, MA
Lindholm, PF
Kajdacsy-Balla, A
Kaul, S
Campell, WB
机构
[1] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
关键词
cell invasion; cyclooxygenase-2; prostaglandins; prostate cancer;
D O I
10.1023/A:1020915914376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PC-3 Low Invasive cells and the PC-3 High Invasive cells were used to investigate the correlation of the COX-2 expression and its arachidonic acid metabolites, prostaglandins, with their invasiveness through Matrigel(R) using a Boyden chamber assay. The COX-2 expression in PC-3 High Invasive cells was approximately 3-fold higher than in PC-3 Low Invasive cells while the COX-1 expression was similar in both cell sublines. When incubated with arachidonic acid, PGE(2) was the major prostaglandin produced by these cells. PC-3 High Invasive cells produced PGE(2) approximately 2.5-fold higher than PC-3 Low Invasive cells. PGD(2) was the second most abundant prostaglandin produced by these cells. Both indomethacin (a nonspecific COX inhibitor) and NS-398 (a specific COX-2 inhibitor) inhibited the production of prostaglandins and the cell invasion. PGE(2) alone did not induce the cell invasion of PC-3 Low Invasive cells. However, PGE(2) reversed the inhibition of cell invasion by NS-398 and enhanced the cell invasion of the PC-3 High Invasive cells. In contrast, PGD(2) slightly inhibited the cell invasion. These results suggest that in the PC-3 Low Invasive cells, COX-2-derived PGE(2) may not be sufficient to induce cell invasion while in the PC-3 High Invasive cells, PGE(2) may be sufficient to act as an enhancer for the cell invasion. Further, PGD(2) may represent a weak inhibitor and counteracts the effect of PGE(2) in the cell invasion.
引用
收藏
页码:593 / 601
页数:9
相关论文
共 75 条
[1]  
Achiwa H, 1999, CLIN CANCER RES, V5, P1001
[2]  
ALBERTS DS, 1995, J CELL BIOCHEM, P18
[3]   Cyclooxygenase and lipoxygenase inhibitors in cancer therapy [J].
Ara, G ;
Teicher, BA .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1996, 54 (01) :3-16
[4]  
Attiga FA, 2000, CANCER RES, V60, P4629
[5]   Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids [J].
Bao, Y ;
Pucci, ML ;
Chan, BS ;
Lu, R ;
Ito, S ;
Schuster, VL .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 282 (06) :F1103-F1110
[6]   PURIFICATION, CHARACTERIZATION AND SELECTIVE-INHIBITION OF HUMAN PROSTAGLANDIN-G/H SYNTHASE-1 AND SYNTHASE-2 EXPRESSED IN THE BACULOVIRUS SYSTEM [J].
BARNETT, J ;
CHOW, J ;
IVES, D ;
CHIOU, M ;
MACKENZIE, R ;
OSEN, E ;
NGUYEN, B ;
TSING, S ;
BACH, C ;
FREIRE, J ;
CHAN, H ;
SIGAL, E ;
RAMESHA, C .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (01) :130-139
[7]   Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT" [J].
Chan, BS ;
Satriano, JA ;
Pucci, M ;
Schuster, VL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (12) :6689-6697
[8]   ARACHIDONIC-ACID METABOLISM IN BENIGN AND MALIGNANT PROSTATIC TISSUE IN-VITRO - EFFECTS OF FATTY-ACIDS AND CYCLOOXYGENASE INHIBITORS [J].
CHAUDRY, AA ;
WAHLE, KWJ ;
MCCLINTON, S ;
MOFFAT, LEF .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :176-180
[9]  
Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO
[10]  
2-#